BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8088323)

  • 1. Wortmannin, an inhibitor of phospholipase D activation, selectively blocks major histocompatibility complex class II-restricted antigen presentation.
    Carrasco-Marín E; Alvarez-Domínguez C; Leyva-Cobián F
    Eur J Immunol; 1994 Sep; 24(9):2031-9. PubMed ID: 8088323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of thymus-independent type 2 antigens on MHC class II-restricted antigen presentation: comparative analysis of carbohydrate structures and the antigen presenting cell.
    González-Fernández M; Carrasco-Marín E; Alvarez-Domínguez C; Outschoorn IM; Leyva-Cobián F
    Cell Immunol; 1997 Feb; 176(1):1-13. PubMed ID: 9070312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell.
    Lombard-Platlet S; Bertolino P; Deng H; Gerlier D; Rabourdin-Combe C
    Immunology; 1993 Dec; 80(4):566-73. PubMed ID: 7508420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells.
    Guéry JC; Adorini L
    J Immunol; 1995 Jan; 154(2):536-44. PubMed ID: 7529278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional differences and complementation between dendritic cells and macrophages in T-cell activation.
    Guidos C; Sinha AA; Lee KC
    Immunology; 1987 Jul; 61(3):269-76. PubMed ID: 2956179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
    Svensson M; Pfeifer J; Stockinger B; Wick MJ
    Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excessive degradation of intracellular protein in macrophages prevents presentation in the context of major histocompatibility complex class II molecules.
    Brazil MI; Weiss S; Stockinger B
    Eur J Immunol; 1997 Jun; 27(6):1506-14. PubMed ID: 9209504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen presentation to T cell lines and clones by peritoneal macrophages, peritoneal B cells and antigen-specific B cell hybridomas.
    Zimecki M; Abruzzini AF; Pierce CW; Kapp JA
    Arch Immunol Ther Exp (Warsz); 1988; 36(4):409-22. PubMed ID: 2471477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing.
    Moss CX; Villadangos JA; Watts C
    Eur J Immunol; 2005 Dec; 35(12):3442-51. PubMed ID: 16259009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-mediated transfer of major histocompatibility class II I-Ab and I-Abm12 genes into B lymphoma cells: molecular and functional analysis of introduced antigens.
    Ben-Nun A; Choi E; McIntyre KR; Leeman SA; McKean DJ; Seidman JG; Glimcher LH
    J Immunol; 1985 Aug; 135(2):1456-64. PubMed ID: 3925010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC class II-restricted presentation of native protein antigen by B cells is inhibitable by cycloheximide and brefeldin A.
    St-Pierre Y; Watts TH
    J Immunol; 1990 Aug; 145(3):812-8. PubMed ID: 2373860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
    Brocke P; Armandola E; Garbi N; Hämmerling GJ
    Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissection of the functions of antigen-presenting cells in the induction of T cell activation.
    Roska AK; Lipsky PE
    J Immunol; 1985 Nov; 135(5):2953-61. PubMed ID: 3876370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential presentation of hepatitis B S-preS(2) particles and peptides by macrophages and B-cell like antigen-presenting cells.
    Scheerlinck JP; Burssens G; Brys L; Michel A; Hauser P; De Baetselier P
    Immunology; 1991 May; 73(1):88-94. PubMed ID: 2045130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.
    Dang LH; Lien LL; Benacerraf B; Rock KL
    J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capacity of antigen uptake by B cells, fibroblasts or macrophages determines efficiency of presentation of a soluble self antigen (C5) to T lymphocytes.
    Stockinger B
    Eur J Immunol; 1992 May; 22(5):1271-8. PubMed ID: 1577067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing.
    Del Pozo V; De Andrés B; Martín E; Cárdaba B; Fernández JC; Gallardo S; Tramón P; Leyva-Cobian F; Palomino P; Lahoz C
    Eur J Immunol; 1992 Jul; 22(7):1919-25. PubMed ID: 1623930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage presentation of endogenous self-protein: the MHC class II presentation pathway is not accessible to intracellular C5 or alpha 1-antitrypsin.
    Grant CF; Ali R; Povey S; Stockinger B
    Cell Immunol; 1996 Feb; 167(2):230-40. PubMed ID: 8603432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines.
    Kovacsovics-Bankowski M; Rock KL
    Eur J Immunol; 1994 Oct; 24(10):2421-8. PubMed ID: 7925570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells.
    Han S; Kim K; Song Y; Kim H; Kwon J; Lee YH; Lee CK; Lee SJ; Ha N; Kim K
    Arch Pharm Res; 2008 Mar; 31(3):370-6. PubMed ID: 18409052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.